RWE – Patient Viewpoint

Issues and Solutions?

Roger Wilson
CBE MD LLD

Affiliations:
NCRI Consumer Forum, Sarcoma UK, Sarcoma Patients Euronet
Clinical research is not an end in itself

We are looking for how we can deliver the over-riding objectives:

• Better treatments
• Better information to support patients
• Better, more meaningful, outcomes
Short-term small Phase 2 studies – deliver poor quality data

Surrogate endpoints deceive patients and support risk taking. Bias is also an issue – poor quality information

This is drug-centred research
Many patients want the knowledge which comes from rigorous science.

Are we clear about the endpoints which really matter? They unlock understanding.

We need patient-centred research.
Data

Information

Knowledge

Understanding

The target – this is what patients need

No help to patients
“In this large, umbrella analysis of surrogate validation studies, we found most surrogates in oncology had low or modest correlation with OS.”

“Confirmatory trials for one-fifth (19/93) of cancer drug indications approved via the FDA’s accelerated approval pathway demonstrated improvements in overall patient survival.”

Eighty-five indications for 59 cancer drugs were identified. 38% received regular approval, and 62% were granted accelerated approval. 55% of accelerated approvals were later converted to regular approval. Of these, 6 drugs showed overall survival benefit – 10% (Edited).
“The current clinical research enterprise has insufficient safeguards against uninformative clinical trials that do not fulfill the contract between researchers and research participants.”

“… although the regulatory system respects the wishes of those willing to take on more risk, it fails patients preferring more information.”

“The existing literature evaluating patients’ understanding, preferences, and values toward the end point of PFS was severely limited by the heterogeneity of methods, attribute selection, and descriptions used to define PFS to patients.”

A majority of patients 51/90 had 'no idea' or were 'unclear' what PFS meant ...

“Vague, meaningless phrases used to describe the toxic effects of drugs are not helpful to patients or their physicians.”
We need accelerated access to treat, and long term data to inform, patients – Real World Evidence

Real World Data must cover the endpoints which deliver understanding - Overall Survival and Quality of Life

Patients must be routinely involved in developing RWE research studies
The solutions we are looking for:

- Overcoming the tyranny of small Phase 2 studies
- Change drug-centred to patient-centred
- Rigorous science with meaningful endpoints
- Accelerated access and provision of robust data
- Involve patients in developing studies
- Quality of life and PROs – longitudinal studies
- Do we need (some) new study methods?
- Funding/oversight/accountability
References

1 A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Alyson Haslam, Spencer P. Hey, Jennifer Gill, Vinay Prasad
European Journal of Cancer 106 (2019) 196e211 accepted 1 November 2018

2 Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Bishal Gyawali, Spencer Phillips Hey, Aaron S. Kesselheim,
Published online May 28, 2019.

3 An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
Emerson Y. Chen; Vikram Raghunathan; Vinay Prasad
Published online May 28, 2019.

4 Harms From Uninformative Clinical Trials
Deborah A. Zarin, Steven N. Goodman, Jonathan Kimmelman,
JAMA Published online July 25, 2019

5 The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another
Commentary in American Journal of Medicine
Derrick Tao, Sally Schott, Vinay Prasad
DOI: https://doi.org/10.1016/j.amjmed.2018.08.017

6 The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer
A Systematic Review and Qualitative Assessment of the Literature
JAMA Oncol. Published online September 26, 2019. doi:10.1001/jamaoncol.2019.3338

7 Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits.
Fallowfield LJ, Catt SL, May SF, Matthews L, Shilling VM, Simcock R, Westwell S, Jenkins VA

8 Talking about Toxicity — “What We’ve Got Here Is a Failure to Communicate”
Chana A. Sacks, Pamela W. Miller, and Dan L. Longo
NEJM 381;15 nejm.org October 10, 2019